AMPEL BioSolutions

Executive Summary

AMPEL BioSolutions is a precision medicine company that integrates computational biology, RNA analytics, and predictive AI to develop diagnostic and disease management tools for autoimmune and inflammatory diseases. Founded in 2014 and based in Charlottesville, Virginia, the company’s core technology is the AMPEL Genomic Platform (AGP®), which analyzes genomic data to generate a patient-specific 'Genomic Fingerprint.' This enables personalized care by predicting disease flares, guiding treatment selection, and identifying potential drug targets. AMPEL’s first commercial product, LuGENE®, is a blood test for lupus that has shown promise in clinical studies for predicting flares and stratifying patients. The company targets a significant unmet need in autoimmune diseases, which are notoriously heterogeneous and difficult to diagnose and manage. With a focus on both diagnostic and therapeutic decision support, AMPEL is positioned to improve outcomes and reduce healthcare costs. Despite being a private company with limited disclosed funding, its platform approach and first product in lupus—a large and underserved market—suggest meaningful potential. However, commercial traction and regulatory validation remain early-stage. The company’s success will hinge on LuGENE’s adoption and expansion into additional indications.

Upcoming Catalysts (preview)

• Q3 2026LuGENE® commercial launch or major partnership60% success
• Q4 2026Publication of pivotal clinical validation data for LuGENE75% success
• 2027Expansion of AGP platform to another autoimmune indication (e.g., rheumatoid arthritis)40% success